Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue cancer that starts in the middle layer of skin, the dermis. It affects roughly 4.6 people per million each year, making it uncommon but not unheard of. DFSP grows slowly, often over years, and is frequently mistaken for a harmless skin condition before it’s correctly identified.
How DFSP Develops
DFSP is driven by a specific genetic error: a swap of material between chromosomes 17 and 22. This rearrangement fuses two genes that don’t normally interact. One gene normally produces a component of collagen, the structural protein in skin. The other produces a growth factor, a signaling molecule that tells cells to multiply. When these genes fuse, the collagen gene’s always-on switch takes control of the growth factor gene, causing the cell to pump out growth signals nonstop. The cell essentially tells itself to keep dividing, creating a self-fueling loop that drives tumor formation.
This isn’t something caused by lifestyle or environmental exposure. The chromosomal swap occurs spontaneously in a single cell, which then multiplies into a tumor over time.
What DFSP Looks and Feels Like
DFSP typically starts as a flat, firm patch of skin. It can be skin-colored, red-brown, violet, or blue. In its early stages, it often looks like a scar, a keloid, or a common benign growth called a dermatofibroma. This resemblance is a major reason diagnosis gets delayed.
Some cases remain flat for an average of seven years before the lesion begins to thicken and bulge. Over time, the flat plaque develops into one or more raised nodules, which is the “protuberans” (protruding) part of the name. As the tumor grows larger, it can reach several centimeters across, and the overlying skin may develop visible small blood vessels. In advanced cases, the surface can ulcerate and become painful. Early on, though, DFSP is usually painless, which is another reason people don’t seek evaluation quickly.
The tumor is most commonly found on the trunk and the upper parts of the arms and legs. It’s fixed to the skin itself but can usually be moved freely over the deeper tissues underneath, at least initially. In later stages, it may attach to deeper structures like muscle or bone.
Who Gets DFSP
DFSP occurs more frequently in people with darker skin tones and tends to appear in middle-aged adults, though it can develop at any age. A population-based analysis covering 2000 to 2020 found that male sex, older age, larger tumor size, lower household income, and tumors located on the lower extremities were all associated with worse survival outcomes.
How DFSP Is Diagnosed
Diagnosis requires a tissue biopsy. Under the microscope, DFSP has a distinctive appearance: uniform spindle-shaped cells arranged in a pinwheel-like (storiform) pattern. To confirm the diagnosis, pathologists use a staining technique called immunohistochemistry. DFSP cells reliably test positive for a protein marker called CD34, which helps distinguish it from other spindle cell tumors that can look similar.
In uncertain cases, molecular testing can detect the characteristic chromosome 17-22 fusion. This is particularly useful when the biopsy sample is small or the tumor has unusual features. Identifying the specific gene fusion also has treatment implications, since the growth factor produced by the fused gene is a potential drug target.
Surgery: The Primary Treatment
Surgery is the standard treatment for DFSP, and the goal is removing the entire tumor with clear margins. Two main approaches exist, and they differ meaningfully in recurrence rates.
Wide local excision removes the visible tumor plus a surrounding margin of normal-looking tissue. In large pooled analyses, the local recurrence rate after this approach is about 9.4%. The challenge with DFSP is that the tumor sends irregular, finger-like extensions into surrounding tissue that aren’t visible to the naked eye, making it difficult to know whether enough tissue has been removed.
Mohs micrographic surgery addresses this problem by removing tissue in thin layers and examining each one under a microscope before cutting further. This allows the surgeon to trace the tumor’s irregular borders precisely. The local recurrence rate with Mohs surgery is around 1.5%, significantly lower than wide excision. Mohs surgery also tends to spare more healthy tissue, which matters for tumors in cosmetically or functionally sensitive areas like the face, hands, or chest.
The Fibrosarcomatous Variant
Most DFSP behaves in a locally aggressive but relatively predictable way: it invades surrounding tissue but rarely spreads to distant organs. The ordinary form has a distant metastasis rate of roughly 1.7%. However, a more aggressive subtype called fibrosarcomatous DFSP (FS-DFSP) carries substantially higher risk.
In fibrosarcomatous transformation, part of the tumor shifts to a higher-grade pattern with more rapidly dividing cells. This variant has a distant metastasis rate of 10 to 15%, and one study found metastasis in 57% of FS-DFSP cases compared to 1.7% of ordinary DFSP cases. The difference in outcomes is stark: five-year survival in that study was 100% for ordinary DFSP but dropped to 25.7% for the fibrosarcomatous variant. FS-DFSP also has an unusual tendency to spread beyond the lungs to sites like bone and soft tissue elsewhere in the body, which means follow-up imaging needs to look beyond just chest scans.
Drug Therapy for Advanced Cases
When DFSP can’t be fully removed surgically, or in the rare cases where it has spread, a targeted drug called imatinib offers a treatment option. Imatinib works by blocking the exact growth factor receptor that the tumor’s gene fusion activates. It was approved for unresectable, recurrent, or metastatic DFSP in 2006.
Clinical trials have shown a response rate of roughly 50%, with partial or complete tumor shrinkage in about half to two thirds of treated patients. In some cases, imatinib is used before surgery to shrink a large tumor and make removal easier. One small series reported a mean decrease of nearly 37% in tumor size after three months of treatment, with complete local control maintained up to four years after subsequent surgery. This presurgical (neoadjuvant) approach can be especially valuable when a tumor is in a location where removing a large amount of tissue would cause significant functional or cosmetic problems.
Prognosis and Long-Term Monitoring
For the vast majority of people with standard DFSP, the outlook is excellent. When the tumor is completely removed with clear margins, cure rates are high and distant spread is rare. The main long-term concern is local recurrence, which is why ongoing monitoring matters.
Current guidelines recommend clinical examinations every six months for the first five years after treatment, then annually. During these visits, your doctor will closely examine the surgical site and surrounding skin for any signs of regrowth. Imaging with MRI is generally reserved for tumors that were deep or invasive. For patients with the fibrosarcomatous variant, follow-up is more intensive and includes imaging to watch for metastasis, particularly to the lungs and abdomen. Patient self-examination of the surgical site between appointments is also encouraged, since catching a recurrence early keeps treatment options straightforward.